Silo Pharma closes $4M private placement with warrants that could unlock an additional $7.7M
SILO sits 71% above its 52-week low of $3.315 on elevated volume (1.9× avg).
Summary
Silo Pharma closed a $4 million private placement with warrants that could add $7.7 million more, priced at a premium but highly dilutive. The deal follows a reverse stock split and a proxy to increase authorized shares, highlighting urgent funding needs.
Key Events · Financing and Capital Events · SILO
-
Private Placement Closed
Silo Pharma issued 124,000 shares at $6.452 and pre-funded warrants for 495,965 shares at $6.4519, raising $4 million upfront. Net proceeds after fees are approximately $3.5 million.
-
Warrants Add Potential Dilution
Investors received Series A-3 and A-4 warrants each for 619,965 shares at a $6.21 exercise price, plus placement agent warrants for 46,497 shares at $8.065. If fully exercised, total proceeds could reach $11.7 million but would more than double the outstanding share count.
-
Priced at Premium, But Heavy Overhang
The $6.452 share price represents a 14% premium to the current $5.67 stock price, yet the warrants and recent reverse split context suggest the company needed to offer sweeteners to attract capital.
-
Follows Reverse Split and Proxy for More Shares
This financing comes after a 1-for-15 reverse stock split in June 2026 and a pending shareholder vote to increase authorized shares from 6.67 million to 250 million, indicating ongoing dilution risk.
Analysis · SILO · Life Sciences
Through a private placement of shares and pre-funded warrants, Silo Pharma raised $4 million upfront, with attached warrants offering the potential for another $7.7 million if exercised. The deal was priced at $6.452 per share—a premium to the current $5.67 stock price—but the warrants at a $6.21 exercise price and the placement agent's warrants at $8.065 create significant overhang. Net proceeds of $3.5 million extend the cash runway for a company that recently completed a reverse stock split and is seeking shareholder approval to massively increase authorized shares. The financing is highly dilutive: if all warrants are exercised, the total shares issued could exceed 1.8 million, more than doubling the current outstanding shares. This comes just days after the company filed a proxy to boost authorized shares from 6.67 million to 250 million, signaling ongoing capital needs.
At the time of this filing, SILO was trading at $5.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $3.32 to $15.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.